Table 3.
Dose (g/kg) | HGB (g/L) | RBC (1012/L) | PLT (109/L) | WBC (109/L) | LYM (%) | NEUT (%) | MONO (%) | EO (%) | BASO (%) |
---|---|---|---|---|---|---|---|---|---|
Male | |||||||||
4 | 156.0 ± 5.8 | 8.91 ± 0.53 | 891.2 ± 74.0 | 7.37 ± 1.29 | 80.3 ± 3.5 | 11.1 ± 3.5 | 7.34 ± 2.35 | 1.21 ± 1.13 | 0.07 ± 0.11 |
2 | 156.2 ± 7.5 | 9.03 ± 0.53 | 869.4 ± 118.8 | 7.83 ± 1.53 | 78.4 ± 1.6 | 13.3 ± 1.8 | 7.28 ± 1.24 | 0.93 ± 0.88 | 0.08 ± 0.11 |
1 | 154.6 ± 6.0 | 8.04 ± 0.51 | 880.2 ± 70.3 | 6.94 ± 0.85 | 78.7 ± 2.6 | 13.0 ± 2.2 | 7.02 ± 1.50 | 1.24 ± 0.51 | 0.10 ± 0.12 |
Control | 155.2 ± 4.7 | 8.56 ± 0.72 | 868.0 ± 101.0 | 6.80 ± 1.14 | 79.2 ± 2.3 | 11.8 ± 2.2 | 7.61 ± 1.69 | 1.27 ± 1.16 | 0.09 ± 0.10 |
| |||||||||
Female | |||||||||
4 | 157.0 ± 7.7 | 8.68 ± 0.46 | 884.4 ± 133.6 | 6.72 ± 1.20 | 79.2 ± 2.1 | 13.0 ± 2.0 | 6.70 ± 1.50 | 1.06 ± 0.64 | 0.10 ± 0.09 |
2 | 154.0 ± 5.2 | 8.36 ± 0.85 | 863.4 ± 79.9 | 7.47 ± 0.87 | 79.5 ± 2.1 | 13.2 ± 1.8 | 6.26 ± 1.83 | 1.01 ± 0.71 | 0.08 ± 0.09 |
1 | 152.2 ± 7.0 | 8.07 ± 0.57 | 866.4 ± 102.4 | 6.68 ± 1.60 | 78.4 ± 2.1 | 13.5 ± 2.1 | 7.02 ± 1.86 | 1.10 ± 0.68 | 0.07 ± 0.11 |
Control | 158.0 ± 4.3 | 8.52 ± 0.39 | 886.0 ± 117.5 | 7.03 ± 1.39 | 78.4 ± 4.1 | 13.4 ± 4.0 | 6.92 ± 1.85 | 1.13 ± 0.49 | 0.09 ± 0.07 |
Note: values represent mean ± standard deviation. HGB, hemoglobin concentration; RBC, red blood cell count; PLT, platelet count; WBC, white blood cell count; LYM, percent of lymphocytes; NEUT, percent of neutrophils; MONO, percent of monocytes; EO, percent of eosinophils; BASO, percent of basophils. Values of the treatment groups did not differ statistically from the control according to one-way ANOVA at p < 0.05.